Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties.

Autor:	Pagano PC; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California., Tran LM; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Bendris N; Department of Cell Biology, UT Southwestern Medical Center, Dallas, Texas., O'Byrne S; Department of Bioengineering, UCLA, Los Angeles, California., Tse HT; Department of Bioengineering, UCLA, Los Angeles, California., Sharma S; Department of Chemistry and Biochemistry, UCLA, Los Angeles, California.; California NanoSystems Institute, Los Angeles, California., Hoech JW; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Park SJ; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Liclican EL; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Jing Z; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Li R; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California., Krysan K; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Paul MK; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Fontebasso Y; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Larsen JE; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Hakimi S; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Seki A; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Fishbein MC; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Gimzewski JK; Department of Chemistry and Biochemistry, UCLA, Los Angeles, California.; California NanoSystems Institute, Los Angeles, California., Carlo DD; Department of Bioengineering, UCLA, Los Angeles, California.; California NanoSystems Institute, Los Angeles, California.; Jonsson Comprehensive Cancer Center, Los Angeles, California., Minna JD; Hamon Center for Therapeutic Oncology Research and Departments of Medicine and Pharmacology, UT Southwestern Medical Center, Dallas, Texas., Walser TC; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California., Dubinett SM; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California. sdubinett@mednet.ucla.edu.; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; California NanoSystems Institute, Los Angeles, California.; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.; Jonsson Comprehensive Cancer Center, Los Angeles, California.; VA Greater Los Angeles Health Care System, Los Angeles, California.
Jazyk:	angličtina
Zdroj:	Cancer prevention research (Philadelphia, Pa.) [Cancer Prev Res (Phila)] 2017 Sep; Vol. 10 (9), pp. 514-524. Date of Electronic Publication: 2017 Jul 28.
DOI:	10.1158/1940-6207.CAPR-16-0335
Abstrakt:	Lung cancers are documented to have remarkable intratumoral genetic heterogeneity. However, little is known about the heterogeneity of biophysical properties, such as cell motility, and its relationship to early disease pathogenesis and micrometastatic dissemination. In this study, we identified and selected a subpopulation of highly migratory premalignant airway epithelial cells that were observed to migrate through microscale constrictions at up to 100-fold the rate of the unselected immortalized epithelial cell lines. This enhanced migratory capacity was found to be Rac1-dependent and heritable, as evidenced by maintenance of the phenotype through multiple cell divisions continuing more than 8 weeks after selection. The morphology of this lung epithelial subpopulation was characterized by increased cell protrusion intensity. In a murine model of micrometastatic seeding and pulmonary colonization, the motility-selected premalignant cells exhibit both enhanced survival in short-term assays and enhanced outgrowth of premalignant lesions in longer-term assays, thus overcoming important aspects of "metastatic inefficiency." Overall, our findings indicate that among immortalized premalignant airway epithelial cell lines, subpopulations with heritable motility-related biophysical properties exist, and these may explain micrometastatic seeding occurring early in the pathogenesis of lung cancer. Understanding, targeting, and preventing these critical biophysical traits and their underlying molecular mechanisms may provide a new approach to prevent metastatic behavior. Cancer Prev Res; 10(9); 514-24. ©2017 AACR See related editorial by Hynds and Janes, p. 491 . (©2017 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu